New updates have been reported about Insilico Medicine.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Insilico Medicine has nominated ISM0387 as its 30th AI-discovered preclinical candidate and the first developmental drug candidate discovered and advanced entirely in the UAE, underscoring the company’s global expansion and capabilities in Abu Dhabi. Developed by a local team using Insilico’s Pharma.AI and Chemistry42 platforms, the MTA-cooperative PRMT5 inhibitor targets MTAP-deleted cancers, with strong central nervous system penetration and promising preclinical data in glioblastoma models, positioning the asset as a potential high-value oncology program.
The ISM0387 program completed the early discovery workflow—from molecular design through lead optimization to preclinical nomination—in under 12 months, versus a traditional 4.5-year industry benchmark, reinforcing Insilico’s claim of step-change R&D efficiency and capital productivity. Supported by the Emirates Drug Establishment, Abu Dhabi Investment Office and the Department of Health Abu Dhabi, the program anchors Insilico’s broader UAE strategy, which includes a 40-person AI and quantum R&D hub in Masdar City, multiple academic partnerships, and a growing pipeline of over 40 assets with 12 IND-cleared candidates and 3 in Phase II, signaling both a maturing commercial pipeline and a strategic manufacturing and export opportunity from Abu Dhabi.